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1  | INTRODUC TION
Over the years, many studies have been conducted to identify prog‐
nostic and predictive markers for head and neck squamous cell carci‐
noma (HNSCC).1 To date, prognostic markers such as age, TNM‐stage 
and histological type determine decision‐making regarding the most 
optimal treatment strategy. In oncogenesis, cell proliferation is one of 
the most essential biological processes and may therefore be a strong 
predictive and prognostic marker.2 Ki‐67 is a nuclear marker that is 
present in all phases of the cell cycle but absent in resting cells (G0 
phase).3 Therefore, Ki‐67 is an ideal marker to quantify the relative 
amount of proliferative neoplastic cells within tumour tissue, defined 
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Objectives: Ambiguous	 results	have	been	 reported	on	 the	predictive	value	of	 the	
Ki‐67	proliferation	index	(Ki‐67	PI)	regarding	local	control	(LC)	and	survival	after	pri‐
mary	radiotherapy	(RT)	in	early‐stage	laryngeal	squamous	cell	cancer	(LSCC).	Small	
study size, heterogenic inclusion, variations in immunostaining and cut‐off values are 





Whitney U‐tests, logistic and Cox regression analyses were performed to assess as‐
sociations	between	Ki‐67	PI,	clinicopathological	variables,	LC	and	DSS.
Results: In multivariate Cox regression analysis, poor tumour differentiation (HR 2.20; 
95% CI 1.06‐4.59, P	=	.04)	and	alcohol	use	(HR	2.84,	95%	CI	1.20‐6.71;	P = .02) were 
independent	predictors	for	LC.	Lymph	node	positivity	was	an	independent	predictor	
for	DSS	(HR	3.16,	95%	CI	1.16‐8.64;	P	=	.03).	Ki‐67	PI	was	not	associated	with	LC	(HR	
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as the Ki‐67 proliferation index (Ki‐67 PI). However, the results of ear‐
lier studies investigating the relationship between the Ki‐67 PI, local 
control	(LC)	and	survival	after	primary	RT	in	laryngeal	squamous	cell	
cancer	(LSCC)	are	not	unambiguous,	as	shown	in	Table	1.4‐14 Possible 
explanations for these differences are variations in patient group fac‐
tors, immunostaining and scoring‐related factors.15‐17
The aim of this study was to assess the value of Ki‐67 PI in pre‐
dicting	LC	and	disease‐specific	survival	(DSS)	after	primary	RT	in	a	
well‐defined consecutive series of patients with early‐stage (T1‐T2) 
LSCC.	By	using	standardised	and	automated	immunohistochemistry	
along	with	digital	image	analysis	(DIA)	to	assess	the	Ki‐67	PI,	we	re‐
duced staining and scoring variability.
2  | PATIENTS AND METHODS
2.1 | Patients
Patients	treated	for	LSCC	at	our	institution	are	included	in	a	database	
by the Netherlands Cancer Registry (NCR) by using the results of the 
nationwide network and registry of histo‐ and cytopathology in the 
Netherlands	(PALGA).	Retrospectively,	data	from	the	hospital	con‐
sisting of date of birth, sex, tumour site, TNM status, tumour classi‐
fication and therapy modality are collected.18,19 From this database, 
a consecutive series of patients was included in the current study 
who were (a) diagnosed between 1990 and 2012; (b) with a primary 
T1‐T2	biopsy‐proven	LSCC;	(c)	had	received	and	completed	primary	
RT with curative intent; (d) had a minimum follow‐up of 5 years (if 
not deceased); and (e) had biopsy tissue available in the biobank at 
the Department of Pathology of our institution. Patients who had a 
coincidental lung carcinoma, multiple HNSCC or previous radiation 
or	surgery	of	 the	head	and	neck	 region	were	excluded.	Additional	
clinical, histopathological and follow‐up data were retrospectively 
collected. Initially, 317 patients could be included. Sufficient biopsy 
material	was	available	 in	238	cases.	After	Haematoxylin	and	Eosin	
(HE) staining and reviewing by a head & neck pathologist, 30 biopsy 
specimens were additionally excluded because of insufficient inva‐
sive tumour tissue within the biopsy material. This resulted in a co‐
hort	of	208	patients.	The	majority	of	included	patients	were	used	in	
previous studies regarding the evaluation of other biomarkers.20‐22
2.2 | Ethical considerations
According	to	the	Central	Committee	on	Research	involving	Human	
Subjects (CCMO), this type of study did not require approval from 
an ethics committee in the Netherlands. This study was approved 
by the Privacy Review Board of the NCR by following “The Code of 
Conduct for the Use of Data in Health Research” of the CCMO.23
2.3 | Treatment
All	 patients	 were	 treated	 by	 a	 multidisciplinary	 head	 &	 neck	 team.	
Patients received primary RT with curative intent using 6MV linear ac‐
celerator equipment as previously described.20‐22 In short, T1 tumours 
received 2 Gy fractions five times weekly with a total dose of 66 Gy. T2 
tumours were treated with six fractions weekly to a total dose of 70 Gy. 
In case of lymph node metastasis, a total dose of 46 Gy was electively 
delivered to the primary planning target volume together with an ad‐
ditional boost of 70 Gy to the primary tumour and pathologic lymph 
nodes. From the year 2000 onwards, planning of field arrangements 
was performed by using contrast‐enhanced computed tomography 
(CT). Before 2000, this was calculated by direct simulation (Figure 1).
2.4 | Follow‐up
All	patients	had	standardised	follow‐up	after	completing	RT	in	ac‐
cordance with the Dutch Working Party on Head and Neck Tumours 
(NWHHT) guidelines.24 For the first 2 years, the otorhinolaryngol‐
ogy and radiotherapy department alternately performed physical 
examination	with	laryngoscopy	every	3	months.	After	2	years,	this	
was alternately performed every 6 months up till 5 years after com‐
pleting radiation treatment. Patients were discharged from follow‐
up after 5 years if no evidence of disease was found.
2.5 | Immunohistochemistry
All	 tumour	 material	 was	 formalin‐fixed	 and	 paraffin‐embedded.	
Using a standard microtome, 3 µm sections were cut from the tu‐
mour paraffin blocks. Immunohistochemistry for Ki‐67 (CONFIRM® 
anti‐Ki‐67	 [30‐9]	 Rabbit	 Monoclonal	 Primary	 Antibody,	 Ventana	
Medical Systems) was performed using the automated Benchmark® 
platform (Ventana Medical Systems) according to the manufactur‐
er's recommendations and protocol. The antibody was pre‐diluted 
by the supplier.
Key points
•	 Ambiguous	results	 regarding	the	predictive	value	of	 the	
Ki‐67 proliferation index regarding local control and sur‐
vival after primary radiotherapy have been reported in 
early‐stage laryngeal squamous cell cancer.
• Small study size, heterogeneous inclusion, variations in 
immunostaining and cut‐off values are factors attributing 
to these contradictory results.
• We used a well‐defined series of T1‐T2 laryngeal tumours 
treated with radiotherapy, standardised automatic immu‐
nostaining and automatic digital scoring.
• Standardised and automated staining minimises vari‐
able staining intensity and improves reproducibility. 
Automated	 digital	 scoring	 eliminates	 interobserver	
variability.
• The Ki‐67 proliferation index was not a predictor for local 
control or disease‐specific survival and therefore should 
not be incorporated in treatment‐related decision‐making 
for early‐stage laryngeal squamous cell cancer.
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2.6 | Evaluation of immunohistochemical staining
A	whole	 tumour	 slide	was	analysed	 in	order	 to	 reduce	 sampling	
error.	All	glass	slides	digitized	using	the	Hamamatsu	Nanozoomer	
HT 2.0 (Hamamatsu Photonics KK, 325‐6). For semi‐automated 
DIA,	 Definiens	 Tissue	 Studio	 3.6	 (Definiens	 AG)	 was	 used.	 
Images were processed in one batch automatically for iden‐
tification and calculation of nuclear staining. Twenty random 
cases were selected and manually counted by the head & neck 
pathologist	 to	 validate	 the	 image	 analysis	 algorithm.	 All	 slides	
contained	 at	 least	 500	 countable	 cells	 (median	 7308,	 range	
509‐121.847).
2.7 | Definitions
LC	was	defined	as	 local	 tumour	 recurrence	at	 the	primary	 tumour	
site within 2 years after RT and was calculated from the date of di‐
agnosis	until	the	date	of	recurrence.	After	this	period	of	2	years,	any	
local recurrence was defined as a second primary tumour. DSS was 
defined as the date of diagnosis until the date of death by disease or 
last date of follow‐up within 5 years.
In the analyses, Ki‐67 PI was considered both as a continuous 
and a dichotomous variable. For dichotimisation, the cut‐off value 
for high vs low Ki‐67 PI was set to 50%, which was defined by the 
median Ki‐67 expression in our cohort. In addition, we also tried to 
compare our data with previously published studies, which used cut‐
off values of 10% and 20%.7‐9,12,13
Alcohol	use	was	defined	as	drinking	one	or	more	units	per	day	
either in the past or at date of diagnosis. The same was applied 
for tobacco use with smoking one or more cigarettes or sigars per 
day.
2.8 | Statistical analysis
Patients were dichotomised based on their Ki‐67 PI, and for correla‐
tions between patient and tumour characteristics, univariate logistic 
TA B L E  1   Patients and disease characteristics related to local recurrence after radiotherapy
First author 























IHC >20% 21 T1‐2N0 Glottic LR	<	12	mo RT = 1.94	(0.32‐11.8)a
Cho et al8
2004














IHC‐TMA Continuous 59 T1‐3N0‐3 Larynx LR	<	2	y RT = 0.71	(0.44‐1.15)
Nichols et al12
2012




IHC >10% 128 T2‐4N0‐+ Larynx Time	to	LR ART = 
Kwon et al14
2015





IHC ≥50% 208 T1‐2N0‐3 Larynx LR	<	2	y RT = 1.58	(0.89‐2.79)
Abbreviations:	ART,	accelerated	radiotherapy;	CI,	confidence	interval;	HR,	hazard	ratio;	HRT,	hypofractionated	radiotherapy;	IHC,	immunohisto‐
chemistry;	LR,	local	recurrence;	mo,	months;	n.s.,	not	specified;	OR,	odds	ratio;	RT,	conventional	radiotherapy;	TMA,	tissue	microarray;	yrs,	years.
a(Subgroup) analysis performed by authors of this article. 
↓High Ki‐67 associated with poor local control. 
↑High Ki‐67 associated with good local control. 
=No relation with local control. 
4  |     KOP et al.
regression was used. In this way, odds ratios (OR) and 95% confi‐
dence intervals (95% CI) were estimated for a high Ki‐67 PI. When 
the Ki‐67 PI was considered as a continuous variable, Mann‐Whitney 
U‐tests were performed. The correlation between the Ki‐67 PI and 
clinicopathological	 characteristics	 was	 evaluated	 for	 LC	 and	 DSS	
by using univariate Cox regression analyses estimating hazard 
ratios	 (HR)	 and	 95%	CI.	 All	 statistical	 tests	were	 two‐sided	 and	 a	
P‐value	≤	.05	was	considered	to	be	statistically	significant.	For	mul‐
tivariate analysis, factors with a P‐value of > .15 were excluded in a 
stepwise manner; factors with a P‐value	of	≤	 .05	were	 included	 in	
the final step. Statistical analyses were performed using SPSS (IBM 
Corp. Released 2015. IBM spss Statistics for Windows, Version 23.0: 
IBM Corp).
3  | RESULTS
Patient and tumour characteristics are described in Table 2. The ma‐
jority of tumours were of glottic origin, had a T2 status, did not have 
lymph node metastasis and were moderately differentiated. Most 
patients were male and median age was 64.4 years.
At	 the	date	of	 analysis,	median	 follow‐up	 time	was	65.2	months	
(range	4‐236).	Local	recurrence	occurred	in	48	patients,	of	which	40	pa‐
tients underwent a total laryngectomy with or without additional neck 
dissection. Eight patients received palliative treatment. The median 
time	to	local	recurrence	was	9.6	months	(range	5‐21).	After	5	years,	152	
patients were still alive, 21 patients died from disease, 26 patients died 
unrelated to disease and nine patients died from unknown causes.
F I G U R E  1   Examples of nucleus 
detection with positive (green) and 
negative (blue) marked tumour cells for 
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Specific	 nuclear	 Ki‐67	 staining	 was	 present	 and	 DIA	 could	 be	
performed in all cases (Figure 1). Median Ki‐67 PI was 49% (range 
4%‐89%).	As	this	approached	the	50%	cut‐off	used	in	other	studies,	
we also used a 50% cut‐off between high and low Ki‐67 PI for com‐
parability. Using a 10% and 20% cut‐off, a high Ki‐67 PI was found 
in	207	cases	(99.5%)	and	199	cases	(95.7%),	respectively.	As	the	low	
Ki‐67 PI group was too small for both cut‐offs (one and nine cases 
respectively), no further statistical analyses were performed using 
these cut‐offs.
In the univariate regression analysis using a 50% cut‐off for the 
Ki‐67 PI, no significant associations between clinicopathological 
variables and Ki‐67 PI were found (Table 3). When treated as a con‐
tinuous variable, no significant associations between Ki‐67 PI and 
the evaluated variables were found (Table 3).
A	significant	negative	association	between	LC	and	poor	tumour	
differentiation	(HR	2.18;	95%	CI	1.06‐4.50,	P = .04), alcohol use (HR 
2.94, 95% CI 1.24‐6.95; P = .01) and tobacco use (HR 7.59; 95% CI 
1.05‐55.02, P = .045) was found. In stepwise multivariate Cox re‐
gression	analysis,	alcohol	use	(HR	2.84,	95%	CI	1.20‐6.71;	P = .02) 
and poor differentiation (HR 2.20; 95% CI 1.06‐4.59, P = .04) were 
independent	predictors	for	worse	LC.	No	associations	between	high	
Ki‐67	PI	and	LC	(HR	1.59;	95%	CI	0.89‐2.81;	P = .11) or KI67 PI as 
a	continuous	variable	and	LC	(HR	2.03;	95%	CI	0.37‐11.14;	P = .42) 
were	found	(Figure	S1A,	Table	4).
In univariate and stepwise multivariate Cox regression analysis, 
a significant negative association was found between lymph node 
positivity	and	DSS	 (HR	3.16,	95%	CI	1.16‐8.64;	P = .03). No asso‐
ciations	were	 found	 between	Ki‐67	PI	 and	DSS	 (HR	0.98;	 95%	CI	
0.57‐1.66; P = .97) or KI67 PI as a continuous variable and DSS (HR 
0.62;	95%	CI	0.05‐8.28;	P = .72) (Figure S1B, Table 5).
4  | DISCUSSION
In	a	well‐defined	series	of	patients	diagnosed	with	T1‐T2	LSCC	and	




From the eleven previously conducted studies, 15 (sub)analy‐
ses were reported or could be calculated using the data and cut‐off 
values provided in the papers (Table 1). Of those, nine did not find 
a	significant	association	between	Ki‐67	PI	and	LC	after	RT.6‐11,13,14 
Two subgroup analyses in one study showed a negative associa‐
tion	between	high	Ki‐67	and	LC	in	both	a	cohort	treated	with	ac‐
celerated	RT	 (ART)	 and	 in	 a	 combined	 cohort	 treated	with	either	
ART	or	conventional	RT	(HR	2.66;	95%	CI	1.17‐6.08	and	HR	5.11;	
95% CI 1.53‐17.06 respectively).5 Nichols et al found a worse local, 
regional or distant control in patients with high Ki‐67 tumours.12 
Three studies showed a significant positive association between 
high	Ki‐67	and	LC	after	RT	using	continuous	values,	and	one	study	
showed a positive association using a 50% cut‐off (no HR or 95% 
CI was given or could be calculated).4,9,10 However, selection bias 
may have influenced the outcome of these studies as in one of the 
studies 36 patients were randomly selected from a larger cohort of 
128	patients,9 another study included only 24 patients with a glottic 
carcinoma involving the anterior commissure in a 10‐year period. 
The study of Rafferty et al only describes 50 patients from a pro‐
spective database, which included patients since 1960.15 Moreover, 
no multivariate analyses to correct for possible confounding factors 
were conducted to verify their significant associations in univariate 
analyses. The results of the current study are in line with results 





TA B L E  2   Pre‐treatment Clinical and Tumour Characteristics (N 
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From five subanalyses of the four studies that assessed the asso‐
ciation between Ki‐67 and survival, none found a difference in OS,5,8 
DSS5,13 or survival (not otherwise specified).10 In one paper, worse 
regional control and metastasis‐free survival were reported.13	 A	
confounder	for	this	result	might	be	the	inclusion	of	advanced	LSCC,	
which has a much higher tendency to metastasise (regionally). Our 
study	only	consisted	of	early‐stage	LSCC.	The	role	of	Ki‐67	 in	ad‐
vanced tumours could be the subject of a follow‐up study.
Consensus on Ki‐67 staining protocols, Ki‐67 antibodies and 
scoring methods is still lacking. The published cut‐offs for high vs 
low Ki‐67 PI varied between 10%, 20% and 50%, along with con‐
tinuous values. We believe tumour markers without pre‐set cut‐
off value (ie continuous values) are deemed less fit as diagnostic 




needed in order to have better comparability across studies. Despite 
this lack of consensus, this seems not to be explanatory for the dif‐
ferent outcomes.
In our cohort, we found a relatively high Ki‐67 PI compared 
with other studies. One of the explanations might be that we used 
marked HE slides to accurately determine and select neoplastic re‐
gions within the digitised Ki‐67 slide. Our digital image algorithm 
solely selected neoplastic cells and excluded non‐tumour cells re‐
sulting in an accurate calculation of the Ki‐67 PI. Rademakers et al 
who	also	used	DIA	on	whole	tumour	section	slides	do	not	explicitly	
state they adjusted scoring for non‐neoplastic regions; which could 
have led to a lower ratio of Ki‐67 positive cells.13	Also,	intratumour	
heterogeneity may lead to lower Ki‐67 PI if the incorrect region 
within the tumour is counted. Others studies predominately used 
manual counting. Most studies, if reported, counted smaller regions 
of the whole tumour, which could lead to selection bias by sampling 
error and interobserver variability.5,6,8‐10
For breast carcinoma, Dowsett et al recommend counting 





OR (95% CI) P value P valuea
Age	(continuous) 208 1.01 (0.99‐1.04) .32 n/a
Age,	years     
<64 98 1   
≥64 110 1.27 (0.73‐2.20) .39 .74
Gender     
Female 22 1   
Male 186 0.75	(0.31‐1.82) .52 .20
Alcohol     
No 57 1   
Yes	(≥1	units/d) 135 1.15 (0.62‐2.15) .65 .86
Tobacco use     
No 26 1   
Yes	(≥1	cig/d) 176 0.91	(0.40‐2.08) .83 .44
Subsite     
Glottic 146 1   
Supraglottic 62 1.77 (0.97‐3.24) .62 .10
cT‐status     
T1 84 1   
T2 124 1.03	(0.59‐1.80) .93 .26
cN‐status     
N0 188 1   
N+ 20 2.16	(0.82‐5.65) .12 .12
Differentiation     
Well/moderate 186 1   
Poor 22 1.34 (0.55‐3.25) .52 .66
Abbreviations:	95%	CI,	95%	Confidence	Interval;	Ki‐67	PI,	Ki‐67	proliferation	index;	n/a,	not	ap‐
plicable; OR, Odds Ratio.
aMann‐Whitney U Test. 
TA B L E  3   Patient and tumour 
characteristics	related	to	high	(≥50%)	
Ki‐67 PI (univariate logistic regression 
analyses) and continuous Ki‐67 values 
(Mann‐Whitney U‐Test)
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proliferation heterogeneity.15 With our automated analysis, a me‐
dian	 of	 7308	 cells	 (ranging	 509‐121.847)	was	 counted	 in	 a	 stan‐
dardised, fast, reliable and reproducible manner. We previously 
validated	the	use	of	DIA	for	Ki‐67	in	breast	carcinoma	and	found	
a high interobserver agreement between manual and automated 
Ki‐67 scoring.25
Manual immunohistochemical staining is a time‐consuming 
process and leads to variable staining intensity. Interlaboratory 
variety is clearly illustrated in the study of Polley et al, were they 
investigated the interlaboratory reproducibility for Ki‐67 staining 
in	breast	cancer	cases	among	eight	North	American	and	European	
laboratories.26	A	moderate	reproducibility	across	the	laboratories	
was found when they used their own scoring methodology on sec‐
tions stained in a central laboratory. This reproducibility declined 
even further when both staining and scoring were done locally. 
By using a standardised and automated staining platform with a 
pre‐diluted antibody by the supplier, we minimised this problem 




primary RT, the clinicopathological characteristics alcohol use and 
poor tumour differentiation were independent predictors for worse 
LC.	 Lymph	 node	 positivity	was	 a	 negative	 predictor	 for	DSS.	 The	
Ki‐67	PI	however	did	not	predict	outcome	regarding	LC	or	DSS	after	
treatment. Therefore, the Ki‐67 PI should not be incorporated in 
treatment‐related	decision‐making	for	LSCC.
Characteristics Total
LC (univariate) LC (multivariate)
HR (95% CI) P value HR (95% CI) P value
Age	(continuous) 208 0.99 (0.97‐1.02) .71 a  
Gender
Female 22 1    
Male 186 1.29 (0.46‐3.60) .62 a  
Alcohol	use
No 57 1    
Yes	(≥1	units/d) 135 2.94 (1.24‐6.95) .01 2.84 (1.20‐6.71) .02
Tobacco use
No 26 1    
Yes	(≥1	cig/d) 176 7.59 (1.05‐55.02) .045 6.78	(0.93‐49.25) .06
Subsite
Glottic 146 1    
Supraglottic 62 1.21 (0.66‐2.20) .54 a  
cT‐status
T1 84 1    
T2 124 1.43	(0.78‐2.61) .24 a  
cN‐status
N0 188 1    
N+ 20 1.68	(0.75‐3.75) .20 a  
Differentiation
Well/moderate 186 1    
Poor 22 2.18 (1.06‐4.50) .04 2.20 (1.06‐4.59) .04
Ki‐67 PI
Low 108 1    
High 100 1.59	(0.89‐2.81) .12 b  
Ki‐67 PI 
(continuous)
208 2.03 (0.37‐11.14) .42 a  
Abbreviations:	95%	CI,	95%	Confidence	Interval;	HR,	Hazard	Ratio;	Ki‐67	PI,	Ki‐67	proliferation	
index;	LC,	Local	control.
Significant results are shown in bold.
aNot included in multivariate analysis. 
bNot included in final step of multivariate analysis. 
TA B L E  4   Patient and tumour 
characteristics related to local control 
(univariate and multivariate cox regression 
analyses)
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